The 2024 ACC/AHA/ACCP/HRS guidelines provide updated evidence-based recommendations for atrial fibrillation management, focusing on anticoagulation, rate and rhythm control, and risk factors.
This review summarizes the 2024 updated guidelines for atrial fibrillation management to assist nurses and nurse practitioners in understanding current evidence-based care.
ABSTRACT: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice worldwide. In 2024, the American College of Cardiology, American Heart Association, American College of Clinical Pharmacy, and Heart Rhythm Society released updated guidelines on the management of AF, offering comprehensive, evidence-based recommendations to support safe and effective care. This article highlights three core components of AF management: anticoagulation in nonvalvular AF, rate control, and rhythm control. The aim is to help RNs and NPs better understand the scientific rationale behind the most recent guideline updates. Practical considerations related to anticoagulation are addressed, including the use of the CHA2DS2-VASc score, the role of direct oral anticoagulants (DOACs) compared with vitamin K antagonists, and the agents used to reverse the anticoagulation effects of DOACs. The article also compares the effectiveness of rate control with that of rhythm control, with an overview of pharmacological and electrical cardioversion strategies. Finally, the article explores the importance of managing modifiable risk factors.
Cook et al. (Thu,) conducted a review in Atrial fibrillation. 2024 ACC/AHA/ACCP/HRS Guidelines was evaluated. The 2024 ACC/AHA/ACCP/HRS guidelines provide updated evidence-based recommendations for atrial fibrillation management, focusing on anticoagulation, rate and rhythm control, and risk factors.